In 2023, Croatia led global antihypertensive medicine sales per capita with an 8.21% increase. Slovakia and Italy saw declines of 0.49% and 3.04% respectively, while the Czech Republic had a notable decline of 4.07%. Canada experienced a modest increase of 2.59%, unlike Greece and Latvia, which faced declines of 4.9% and 6.66% respectively. Estonia showed a slight increase of 2.13%, whereas Costa Rica reported the highest rise at 8.45% per capita.
Future trends indicate growing demand driven by aging populations and increasing hypertension awareness. Monitoring economic fluctuations and healthcare policies will be vital to understand variations across regions.
Top countries in Antihypertensive Medicine Sales by Country
| # | 9 Countries | US Dollars Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Croatia | 23 | 2023 | +3.14% | +8.21% | View data |
| 2 | 2 Slovakia | 4 | 2023 | +2.56% | -0.49% | View data |
| 3 | 3 Italy | 3 | 2023 | 0% | -3.04% | View data |
| 4 | 4 Czech Republic | 2.6 | 2023 | 0% | -4.07% | View data |
| 5 | 5 Canada | 2.5 | 2023 | +13.64% | +2.59% | View data |
| 6 | 6 Greece | 2.1 | 2023 | -8.7% | -4.9% | View data |
| 7 | 7 Latvia | 1.7 | 2023 | 0% | -6.66% | View data |
| 8 | 8 Estonia | 1 | 2023 | 0% | +2.13% | View data |
| 9 | 9 Costa Rica | 0.3 | 2023 | +50% | +8.45% | View data |
